Rare Disease Leadership Leverage GeneDx's leadership in rare disease genomics and the Infinity dataset, along with FDA Breakthrough Device Designation, to drive broader adoption of ExomeDx and GenomeDx among large health systems and specialty clinics; emphasize faster, more actionable diagnoses and stronger clinical and payer value.

Data Collaboration The Infinity dataset enables strategic partnerships with pharma, biotech and CROs for biomarker discovery, patient stratification and translational research; propose data licensing, joint studies and analytic services to create new revenue streams.

Integrated Platform A modern tech stack including Snowflake and cloud based data sharing supports secure integration with electronic health records and CLIA compliant workflows; offer end to end genomics data platforms, customized analytics dashboards and automation to healthcare providers.

Risk Management Public regulatory and investor actions around GeneDx highlight the need for robust governance, data provenance and compliance; position offerings around data quality assurance, transparent reporting and risk management to reassure hospitals and payers.

Growth Channels With broad disease coverage and scalable operations, pursue enterprise partnerships with regional health systems, academic medical centers and diagnostic labs to expand ExomeDx and GenomeDx footprints; explore bundled service contracts, education programs and multi year agreements to accelerate adoption.